The DOI matches its Crossref record.
Randomized Selection Design Trial Evaluating CD8+-Enriched Versus Unselected Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy for Patients With Melanoma
Open accessAbstract
Purpose: Adoptive cell therapy (ACT) with autologous tumor-infiltrating lymphocytes (TILs) and high-dose interleukin-2 (IL-2) administered to lymphodepleted patients with melanoma can cause durable tumor regressions. The optimal TIL product for ACT is unknown. Patients and Methods: Patients with metastatic melanoma were prospectively assigned to receive unselected young TILs versus CD8+-enriched TILs. All patients received lymphodepleting chemotherapy and high-dose IL-2 therapy and were assessed for response, toxicity, survival, and immunologic end points. Results: Thirty-four patients received unselected young TILs with a median of 8.0% CD4+lymphocytes, and 35 patients received CD8+-enriched TILs with a median of 0.3% CD4+lymphocytes. One month after TIL infusion, patients who received CD8+-enriched TILs had significantly fewer CD4+peripheral blood lymphocytes (P = .01). Twelve patients responded to therapy with unselected young TILs (according to Response Evaluation Criteria in Solid Tumors [RECIST]), and seven patients responded to CD8+-enriched TILs (35% v 20%; not significant). Retrospective studies showed a significant association between response to treatment and interferon gamma secretion by the infused TILs in response to autologous tumor (P = .04), and in the subgroup of patients who received TILs from subcutaneous tumors, eight of 15 patients receiving unselected young TILs responded but none of eight patients receiving CD8+-enriched TILs responded. Conclusion: A randomized selection design trial was feasible for improving individualized TIL therapy. Since the evidence indicates that CD8+-enriched TILs are not more potent therapeutically and they are more laborious to prepare, future studies should focus on unselected young TILs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
Gros, A., Robbins, P. F., Yao, X., Li, Y. F., Turcotte, S., Tran, E., Wunderlich, J. R., Mixon, A., Farid, S., Dudley, M. E., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73639 · Cited by 1,111
Self-citationImmunity, inflammation, and cancer: an eternal fight between good and evil
Shalapour, S., & Karin, M. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80007 · Cited by 698
Schumacher, T. N., Scheper, W., & Kvistborg, P. (2019) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042617-053402 · Cited by 574
Interleukin 12: still a promising candidate for tumor immunotherapy?
Lasek, W., Zagożdżon, R., & Jakobisiak, M. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1523-1 · Cited by 495
Metadata
- Authors
- Dudley, M. E., Gross, C. A., Somerville, R. P. T., Hong, Y., Schaub, N. P., Rosati, S. F., White, D. E., Nathan, D., Restifo, N. P., Steinberg, S. M., Wunderlich, J. R., Kammula, U. S., Sherry, R. M., Yang, J. C., Phan, G. Q., Hughes, M. S., Laurencot, C. M., & Rosenberg, S. A.
- Venue
- Journal of Clinical Oncology
- Published
- 2013-06-10
- Volume
- 31
- Issue
- 17
- Pages
- 2152-2159
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1965029629
- Cited by
- 235
- References
- 0
- FWCI
- 13.75
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomized Selection Design Trial Evaluating CD8+-Enriched Versus Unselected Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy for Patients With Melanoma. https://app.cochat.ai/papers/10.1200/jco.2012.46.6441
- The paper
- Dudley, M. E., Gross, C. A., Somerville, R. P. T., Hong, Y., Schaub, N. P., Rosati, S. F., White, D. E., Nathan, D., Restifo, N. P., Steinberg, S. M., Wunderlich, J. R., Kammula, U. S., Sherry, R. M., Yang, J. C., Phan, G. Q., Hughes, M. S., Laurencot, C. M., & Rosenberg, S. A. (2013). Randomized Selection Design Trial Evaluating CD8+-Enriched Versus Unselected Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy for Patients With Melanoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2012.46.6441
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.